ELI LILLY & CO (LLY) Stock News
NYSE:LLY - New York Stock Exchange, Inc. - US5324571083 - Common Stock - Currency: USD
LLY Latest News, Press Relases and Analysis
Discover which S&P500 stocks are making waves on Friday.
Let's delve into the developments on the US markets one hour before the close of the markets on Friday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Explore the top gainers and losers within the S&P500 index in today's session.
Get insights into the S&P500 index performance on Friday. Explore the top gainers and losers within the S&P500 index in today's session.
3 Red-Hot Growth Stocks to Buy in 2025
Spotify offers a music streaming service and is seeing healthy traction in paid membership, rising profitability and free cash flows. Lyft just turned profitable and free-cash-flow-positive, and has a huge total addressable market that will allow for many more years of growth. It pays to spot promising growth stocks that you can buy and keep for years or even decades.
Autodesk price target raised to $345 from $340 at Rosenblatt
Rosenblatt analyst Blair Abernethy raised the firm’s price target on Autodesk (ADSK) to $345 from $340 and keeps a Buy rating on the shares after the company reported Q1 results marginally ahead of the firm’s forecast. For its updated outlook, the positive impact of forex on Autodesk’s billings growth is now being partially offset by added caution to better reflect macro uncertainty, notes the analyst, who is making “minor adjustments” to the firm’s forecasts post Q1. Published first on TheFly –
Here is Why Oklo (OKLO) Surged Today
The share price of Oklo Inc. (NYSE:OKLO) surged by 23.04% on May 23, 2025. Let’s shed some light on the development. Backed by OpenAI’s Sam Altman, Oklo Inc. (NYSE:OKLO) develops advanced fission power plants to provide clean, reliable, and affordable energy at scale to customers in the United States. Oklo Inc. (NYSE:OKLO) rallied on Friday […]
Cramer's Lightning Round: Eli Lilly is a buy
"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
Mentions: HAL
3 Trades Members of Congress Are Making Right Now
Knowing what Congressional leaders are buying can give investors insight into future legislation that could benefit these companies
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.
The Zacks Analyst Blog Highlights Eli Lilly, GE Aerospace and Amgen
Zacks highlights LLY, GE, and AMGN as top picks, citing strong demand, product pipelines, and defense tailwinds despite some pricing and margin pressures.
Investing for the Long Term: 1 Unstoppable Vanguard ETF to Buy and Hold Forever
2 Growth Stocks to Own for Decades and 1 to Steer Clear Of
Growth is oxygen. But when it evaporates, the consequences can be extreme - ask anyone who bought Cisco in the Dot-Com Bubble (Nvidia?) or newer investors who lived through the 2020 to 2022 COVID cycle.
Cigna Announced a New Agreement for Copay Caps on Eli Lilly and Novo Nordisk Weight Loss Drugs
The Cigna Group (NYSE:CI)’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit insured customers’ monthly out-of-pocket expenses for weight-loss drugs Zepbound and Wegovy to $200. Beginning in the second half of 2025, the program targets businesses that do not already cover these drugs because of their high […]
Was Jim Cramer Right About Danaher Corporation (DHR)?
We recently published a list of Was Jim Cramer Right About These 12 Stocks? In this article, we are going to take a look at where Danaher Corporation (NYSE:DHR) stands against other stocks that Jim Cramer discusses. Back in 2024, on May 15, Mad Money’s Jim Cramer discussed how some long-time outperformers were being overlooked, […]
Lilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of imlunestrant, an investigational oral selective estrogen receptor...
CMS to recover ‘uncollected overpayments’ amid Medicare audits
When announcing a “significant expansion” of its auditing efforts for Medicare Advantage plans, the Centers for Medicare and Medicaid Services said it will collaborate with the Department of Health and Human Services Office of Inspector General to recover uncollected overpayments identified in past audits. Publicly traded companies in the healthcare space include CVS Health (CVS), Centene (CNC), Cigna (CI), Elevance Health (ELV), Humana (HUM), Molina Healthcare (MOH) and UnitedHealth (UNH). Publ
Top Analyst Reports for Eli Lilly, GE Aerospace & Amgen
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), GE Aerospace (GE) and Amgen Inc. (AMGN).
TD Cowen Raises JPMorgan Price Target to $315 After Investor Day
On May 20, TD Cowen updated its evaluation of JPMorgan Chase & Co. (NYSE:JPM), raising its price target from $305 to $315 while maintaining a Buy rating. The change follows the company’s investor day, which provided analysts with greater confidence in the bank’s distinct market position. According to the investor day presentation, JPMorgan Chase & […]
Marjorie Taylor Greene Goes Shopping For Tesla, Netflix, UnitedHealth And More: 19 Stocks The Congresswoman Bought
Rep. Marjorie Taylor Greene (R-Ga.) has been actively buying stocks in 2025 and is back with more than a dozen more trades less than two weeks after her last disclosure. Here's the latest transactions made by the congresswoman in May. What Happened: ...
The market has finally left overbought territory — and why Cramer is watching health-care stocks
The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.
Hims & Hers Stock Drops After Evernorth Announces Cheaper Pricing For Weight-Loss Drugs: Retail’s Dull
Truist noted on Thursday that the $200/month price point is "highly attractive compared to other price points in the market," including Hims & Hers' compounded Semaglutide, Wegovy, and Liraglutide subscription programs.
We’re adding to our position in this out-of-favor, high-quality drugmaker stock
With shares trading at a 52-week low and only 24 times its estimated 2026 EPS, many risks have already been priced in.
Better Weight Loss Stock: Amgen or Viking Therapeutics?
Amgen's weight loss candidate reported mixed phase 2 data, but the company has other weapons. Viking Therapeutics' leading anti-obesity program aced mid-stage studies, and it's not its only promising candidate. Deciding between these two stocks might come down to each investor's style, priorities, and risk tolerance.
US business activity improves in May; inflation poised to accelerate sharply
WASHINGTON (Reuters) -U.S. business activity picked up in May amid a truce in the trade war between Washington and China, but President Donald Trump's sweeping tariffs on imported goods raised prices for companies and consumers. The survey from S&P Global on Thursday hinted at an acceleration in inflation in the coming months and a labor market slowdown, a reminder that stagflation remained a risk for the economy despite steps by the Trump administration to de-escalate trade tensions with Beijing. Manufacturing delivery delays were the longest in 31 months while exports of services, including spending by foreign visitors in the U.S., dropped at the sharpest pace since the COVID-19 pandemic lockdowns in early 2020.
Sanofi to Join Alzheimer's Space With Vigil Neuroscience Buyout
SNY inks an agreement to acquire VIGL and its pipeline candidate VG-3927, which is being developed to treat Alzheimer's disease.
3 No-Brainer Artificial Intelligence (AI) Stocks to Buy Right Now
Alphabet's stock has reached dirt-cheap levels. Investors need to look past the price they could have bought them for just a month ago, as those prices are long gone. Furthermore, investors shouldn't sit on the sidelines waiting for another drop, as it may not come for some time.
Novo Nordisk's former chief makes comeback to steer choice of new CEO
COPENHAGEN/LONDON (Reuters) -Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press conference in Copenhagen: "You ain't seen nothing yet." His appointment as an observer on the board follows the removal on Friday of current CEO Lars Fruergaard Jorgensen by Novo and the Novo Nordisk Foundation - the company's controlling shareholder, which Sorensen chairs. Jorgensen succeeded Sorensen as CEO in 2017.
Mentions: NVO
Wegovy, Zepbound Just Got Cheaper: Cigna Sets $200 Monthly Limit For Weight-Loss Drug Users
Cigna’s Evernorth has reached agreements with Eli Lilly and Novo Nordisk to reduce prices for GLP-1 weight-loss drugs Wegovy and Zepbound
Cigna announces new deal for copay caps on Eli Lilly and Novo Nordisk weight loss drugs
Cigna's pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.
Mentions: CI
Cigna Offers New Weight-Loss Drug Pricing Plan to Boost Use
Cigna Group’s drug benefit unit is offering a new way for health plans to cover expensive weight-loss drugs that it says will make the medicines available to more patients.
Lilly's Kisunla (donanemab) receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's disease
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the Australian Therapeutic Goods Administration (TGA) has granted marketing...
AbCellera Biologics Inc. (ABCL): Analysts See 474% Upside Potential
We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. AbCellera Biologics Inc. (NASDAQ:ABCL) was one of the stocks that was covered in that article. Wall Street analysts believe ABCL has a 474% upside potential over the next 12 months. AbCellera Biologics Inc. (NASDAQ:ABCL) is an AI-powered biotechnology company specializing in antibody […]
AstraZeneca Stock Declines 6% in 3 Months: Time to Buy the Dip?
AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales in 2025.
Market Monitor News May 12 ( NRG Energy, Amazon, Meta Platforms UP - CVS Health DOWN)
Wall Street Surges on Temporary Trade Truce Between US and China
Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session.
Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session.
Top S&P500 movers in Monday's pre-market session
Get insights into the top gainers and losers in the S&P500 index of Monday's pre-market session.
Market Monitor May 9 (Boeing, MicroStrategy UP - Match Group DOWN)
U.S. Markets Rise on Trade Deal Hopes and Boeing Boost
Discover which S&P500 stocks are making waves on Thursday.
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Thursday as we examine the latest happenings in today's session.